83 related articles for article (PubMed ID: 23127338)
1. The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients.
Xu X; Han L; Yang H; Duan L; Zhou B; Zhao Y; Qu J; Ma R; Zhou H; Liu Z
Lung Cancer; 2013 Jan; 79(1):65-72. PubMed ID: 23127338
[TBL] [Abstract][Full Text] [Related]
2. [eIF3a gene polymorphism and chemo-sensitivity to platinum-based drugs in ovarian cancer].
Zhang C; Zhang S; Liu Y; Tian Y; Li X; Zhang Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Jun; 40(6):617-22. PubMed ID: 26164510
[TBL] [Abstract][Full Text] [Related]
3. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
4. Effect of eIF3a on response of lung cancer patients to platinum-based chemotherapy by regulating DNA repair.
Yin JY; Shen J; Dong ZZ; Huang Q; Zhong MZ; Feng DY; Zhou HH; Zhang JT; Liu ZQ
Clin Cancer Res; 2011 Jul; 17(13):4600-9. PubMed ID: 21610145
[TBL] [Abstract][Full Text] [Related]
5. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
[TBL] [Abstract][Full Text] [Related]
6. Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients.
Yin JY; Meng XG; Qian CY; Li XP; Chen J; Zheng Y; Liu R; Zhou HH; Liu ZQ
Acta Pharmacol Sin; 2015 Mar; 36(3):375-84. PubMed ID: 25732572
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
8. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
9. eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.
Zhang Y; Yu JJ; Tian Y; Li ZZ; Zhang CY; Zhang SF; Cao LQ; Zhang Y; Qian CY; Zhang W; Zhou HH; Yin JY; Liu ZQ
Oncotarget; 2015 Sep; 6(28):25441-51. PubMed ID: 26213845
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
11. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
[TBL] [Abstract][Full Text] [Related]
12. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.
Moon YW; Choi SH; Kim YT; Sohn JH; Chang J; Kim SK; Park MS; Chung KY; Lee HJ; Kim JH
Cancer; 2007 May; 109(9):1829-35. PubMed ID: 17366594
[TBL] [Abstract][Full Text] [Related]
13. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.
Xu X; Ren H; Zhou B; Zhao Y; Yuan R; Ma R; Zhou H; Liu Z
Lung Cancer; 2012 Aug; 77(2):438-42. PubMed ID: 22516052
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
15. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
16. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
[TBL] [Abstract][Full Text] [Related]
17. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of platinum analogue-based chemotherapy for advanced esophageal squamous cell carcinoma and prognostic factors].
Yang L; Wang JW; Shi YK
Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1233-7. PubMed ID: 21756792
[TBL] [Abstract][Full Text] [Related]
19. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
Yu D; Zhang X; Liu J; Yuan P; Tan W; Guo Y; Sun T; Zhao D; Yang M; Liu J; Xu B; Lin D
Clin Cancer Res; 2008 May; 14(9):2878-86. PubMed ID: 18451256
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
Iranzo V; Sirera R; Bremnes RM; Blasco A; Jantus-Lewintre E; Tarón M; Berrocal A; Blasco S; Caballero C; Del Pozo N; Rosell R; Camps C
Clin Lung Cancer; 2011 Jul; 12(4):224-30. PubMed ID: 21726821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]